QVT Financial
QVT Financial LP is a privately owned hedge fund sponsor. The firm provides its services to pooled investment vehicles. It invests in the
Business Model:
Revenue: $15.8M
Employees: 2-10
Rankings
Industries / Tags:
Detailed QVT Financial Information
Geographic Data
Address: 1177 Avenue of the Americas
City: New York
State: NY
Zip: 10036
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$443M
Social
Linkedin
Crunchbase
Metrics
4,008,989Website Global Rank
2,982Website Monthly Traffic
Twitter Followers
Description
QVT Financial LP is a privately owned hedge fund sponsor. The firm provides its services to pooled investment vehicles. It invests in public equity and debt across the globe. The firm also invests in alternative investment markets across the globe. It invests in structured finance, private placements, high yield, and distressed debt to create its portfolios. The firm employs convertible arbitrage, investment grade, and capital structure arbitrage techniques along with closed-end fund arbitrage and various relative value-driven equity strategies such as risk arbitrage, fundamental relative value, statistical trades, and other special situation techniques to its investments. QVT Financial is based in New York, New York with an additional office in London, United Kingdom.
Contact Phone:
+12122219143
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2014 | Roivant Sciences | Private Equity Round | 0 |
| 5/2006 | MediaVast | Series C | 15M |
| 11/2013 | Innate Pharma | Post-IPO Equity | 27.3M |
| 5/2022 | Kriya Therapeutics | Series C | 0 |
| 7/2021 | Kriya Therapeutics | Series B | 0 |
| 8/2006 | Magen BioSciences | Series A | 15.4M |
| 11/2018 | Roivant Sciences | Private Equity Round | 0 |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2015 | AveXis | Series D | 65M |
| 6/2007 | Exanet | Venture Round | 18M |
| 12/2014 | Palatin Technologies | Post-IPO Equity | 0 |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 4/2008 | Concert Pharmaceuticals | Series C | 0 |
| 10/2007 | Acceleron Pharma | Series C | 31M |
| 7/2006 | Concert Pharmaceuticals | Series A | 10M |
| 9/2014 | Flex Pharma | Venture Round | 0 |
| 11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
| 5/2020 | Kriya Therapeutics | Series A | 0 |
| 5/2022 | Kriya Therapeutics | Series C | 0 |
| 7/2021 | Kriya Therapeutics | Series B | 0 |
| 5/2020 | Kriya Therapeutics | Series A | 0 |
| 11/2018 | Roivant Sciences | Private Equity Round | 0 |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 9/2015 | AveXis | Series D | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 12/2014 | Palatin Technologies | Post-IPO Equity | 0 |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2014 | Flex Pharma | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
